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ABSTRACT: Background: A minimal clinically impor-
tant difference has not been established for the Abnormal
Involuntary Movement Scale in patients with tardive dyski-
nesia. Valbenazine is a vesicular monoamine transporter
2 inhibitor approved for the treatment of tardive dyskinesia
in adults. Efﬁcacy in randomized, double-blind, placebo-
controlled trials was deﬁned as the change from baseline in
Abnormal Involuntary Movement Scale total score (sum of
items 1-7).
Objectives: To estimate an minimal clinically important dif-
ference for the Abnormal Involuntary Movement Scale
using valbenazine trial data and an anchor-based method.
Methods: Data were pooled from three 6-week double-
blind, placebo-controlled trials: KINECT (NCT01688037),
KINECT 2 (NCT01733121), and KINECT 3 (NCT02274558).
Valbenazine doses were pooled for analyses as follows: “low
dose,” which includes 40 or 50 mg/day; and “high dose,”
which includes 75 or 80 mg/day. Mean changes from
baseline in Abnormal Involuntary Movement Scale total
score were analyzed in all participants (valbenazine- and
placebo-treated) with a Clinical Global Impression of
Change-Tardive Dyskinesia or Patient Global Impression
of Change score of 1 (very much improved) to 3 (minimally
improved).
Results: The least squares mean improvement from base-
line to week 6 in Abnormal Involuntary Movement Scale total
score was signiﬁcantly greater with valbenazine (low dose:
–2.4; high dose: –3.2; both, P < 0.001) versus placebo (–0.7).
Anminimal clinically important difference of 2 points was esti-
mated based on least squares mean changes in Abnormal
Involuntary Movement Scale total score in participants with a
Clinical Global Impression of Change-Tardive Dyskinesia
score ≤3 at week 6 (mean change: –2.2; median change: –2)
or Patient Global Impression of Change score ≤3 at week
6 (mean change: –2.0; median change: –2).
Conclusions: Results from an anchor-based method
indicate that a 2-point decrease in Abnormal Involuntary
Movement Scale total score may be considered clinically
important. © 2019 The Authors. Movement Disorders
published by Wiley Periodicals, Inc. on behalf of Interna-
tional Parkinson and Movement Disorder Society.
Key Words: AIMS; clinical trial; MCID; tardive dyskinesia;
valbenazine
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Tardive dyskinesia (TD) is a hyperkinetic movement
disorder that is associated with exposure to an antipsy-
chotic or other dopamine receptor blocking agent (DRBA),
such as metoclopramide.1,2 Despite the development and
widespread use of second-generation antipsychotics, TD
remains a relevant potential risk of DRBAs.3-6 Two medica-
tions, valbenazine and deutetrabenazine, are now approved
for the treatment of TD in adults. The placebo-controlled
clinical trials of these drugs had some differences in study
design (e.g., treatment duration, eligibility criteria), but both
used the Abnormal InvoluntaryMovement Scale (AIMS)7 to
measure the presence, severity, and changes in TD. Results
from the valbenazine anddeutetrabenazine trials showed that
both compounds had measurable and statistically signiﬁcant
beneﬁts as assessed bymean changes inAIMS total score.8-12
Although the mean change in AIMS total score is a cur-
rent standard for evaluating efﬁcacy in clinical trials, the
implications of this outcome for everyday practice are
unclear. Along with other analytical approaches (e.g.,
Cohen’s effect size, number needed to treat [NNT]), one
way to estimate clinical relevance of recent TD trial results
would be to identify a minimal clinically important differ-
ence (MCID) for the AIMS total score. Two approaches are
generally used to estimate MCIDs: distribution-based,
which relies on a standard deviation (SD) or standard error
of themeasurement; and anchor-based,which uses an exter-
nal measure (e.g., 7-point global assessment scale) as an
independent criterion for improvement.13-15 An MCID for
the AIMS has not been established in patients with TD, pos-
sibly because of the lack of large, well-controlled, and pro-
spectively designed studies in this population. With the
completion of three randomized controlled trials with
valbenazine, a data set is now available that includes AIMS
results for >350 study participants. Moreover, this data set
includes Clinical Global Impression of Change-Tardive
Dyskinesia (CGI-TD) and Patient Global Impression of
Change (PGIC) results, which may be appropriate anchor
scales for estimating anMCID.
Stemming from a Tardive Dyskinesia Assessment
Workshop (TD Workshop) that was convened in October
2016,16 the results presented in this report are intended to
propose a clinically meaningful approach to understand-
ing AIMS results in TD clinical trials. The TD Workshop
participants agreed that multiple analytical approaches to
interpreting AIMS data should be made available. The
MCID estimates proposed in this study are intended to
stand alone. However, as discussed in greater detail later,
they are also part of a larger initiative by the TD Work-
shop participants to explore different types of clinically
meaningful AIMS analyses.
Materials and Methods
Data and Assessments
Full data sets from three 6-week, randomized, double-
blind, placebo-controlled trials (Fig. 1)8-10 were made
available from the study sponsor (Neurocrine Biosciences,
Inc., San Diego, CA) and analyzed post hoc by an indepen-
dent statistician (Veristat, Inc., Southborough, MA). For
efﬁcacy analyses, valbenazine doses were pooled into two
groups as follows: (1) “low dose,” which included partici-
pants who received 50 mg/day in KINECT (including treat-
ment with 100 mg/day for the ﬁrst 2 weeks), 50 mg/day
in KINECT 2, or 40 mg/day in KINECT 3; and (2)
“high dose,” which included participants who received
75 mg/day in KINECT 2 or 80 mg/day in KINECT
3. Participants who received valbenazine 25 mg/day in
KINECT 2 were excluded from analyses. All treatments
(valbenazine and placebo) were pooled for MCID ana-
lyses. Additional information regarding treatment and
study participants are summarized in the Supporting
Information Appendix.
Outcome measures included the AIMS, CGI-TD, and
PGIC. AIMS total score was deﬁned as the sum of items
1 to 7, which focus on severity of abnormal movements
in different body regions. Scoring for each of these seven
items (range, 0 = none to 4 = severe) was based on the
consensus of two central AIMS video raters (movement
disorder specialists) who were blinded to treatment and
study visit (baseline and weeks 2, 4, and 6). Scoring for
the CGI-TD (range, 1 = very much improved to 7 = very
much worsened) was based on clinical evaluation by the
site investigator. Scoring for the PGIC (range, 1 = very
much improved to 7 = very much worsened) was based
on self-report by the study participant.
Statistical Analyses
All analyses were conducted in the pooled intent-to-treat
(ITT) population, deﬁned as participants who received
FIG. 1. Valbenazine studies. Valbenazine dose groups were pooled as
follows: “low dose” (50 mg/day and 100/50 mg/day [KINECT],
50 mg/day [KINECT 2], and 40/day mg [KINECT 3]); and “high dose”
(75 mg/day [KINECT 2], 80 mg/day [KINECT 3]). Participants who
received valbenazine 25 mg/day in KINECT 2 were not included in the
pooled analyses. Participants randomized to valbenazine 80 mg/day
in KINECT 3 received 40 mg/day for 1 week.
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≥1 dose of study drug (placebo or valbenazine) and
had ≥1 postbaseline AIMS assessment. No imputation
methods were used for missing data. Effect of treatment
on TD was based on change from baseline to week 6 in
the AIMS total score, analyzed using an analysis of covari-
ance model that included treatment group, study, and psy-
chiatric diagnosis group as ﬁxed effects and baseline AIMS
total score as a covariate. Two response analyses based on
CGI-TD scores were conducted based on the following
deﬁnitions: score of ≤3 (minimally to very much
improved) at week 6; score ≤2 (much or very much
improved) at week 6. The same criteria were used for
PGIC response. Odds ratios (ORs) for CGI-TD and PGIC
responses were calculated for the pooled valbenazine
dose groups (low-dose and high-dose) and the pooled
placebo group, with P values for valbenazine versus pla-
cebo analyzed using the Pearson chi-square test.
In the clinical trials, CGI-TD and PGIC response analyses
were conducted to identify potential differences between
valbenazine and placebo in terms of treatment effect. For this
analysis, however, the primary function of the response ana-
lyses was to establish anchors for the MCID estimation. As
such, treatment assignment (low-dose valbenazine, high-
dose valbenazine, or placebo) was not taken into consider-
ation in the MCID analysis. Estimation of the AIMSMCID
was investigated based on participants who had aminimal
or better CGI-TD response at week 6 (score ≤3), regardless
of treatment, with supporting analyses based on the more
stringent CGI-TD response deﬁnition (score ≤2) and PGIC
responses (score ≤2 or ≤3). For each response category,
the mean and median AIMS total score change from base-
line to week 6 was analyzed in all participants regardless
of treatment. The mean percent improvement in AIMS
total score was also analyzed based on CGI-TD and PGIC
categories.
Results
In the pooled ITT population, baseline characteristics
were generally similar across treatment groups (Table 1).
Mean improvements from baseline to week 6 in AIMS
total score were signiﬁcantly greater in both valbenazine
dose groups than in the placebo group (Fig. 2). Least
squares mean differences from placebo were –1.7 and
–2.6 in the pooled low- and high-dose valbenazine groups,
respectively. The percentage of participants with minimal
or better CGI-TD improvement (score ≤3 at week 6) was
signiﬁcantly higher with valbenazine high dose versus pla-
cebo (Fig. 3). Both valbenazine doses were found to have
a signiﬁcantly greater percentage of participants meeting
the more rigorous response deﬁnition of “much improved”
or “very much improved” (score ≤2). No statistical signiﬁ-
cance between valbenazine and placebo was found for
either PGIC response analysis (Supporting Information
Appendix; Supporting Information Table S1).
MCID Estimation
Based on participants with a CGI-TD score ≤3 at week
6 (Fig. 4A), the estimated MCID for AIMS total score was
2 points. The mean change from baseline ( standard error
of the mean [SEM]) in AIMS total score was –2.2 (0.2)
and the median change was –2 (range, –13 to 8). These
changes corresponded to a mean percent improvement of
17.2% (3.5%).
Based on participants with a CGI-TD score ≤2 at week
6 (Fig. 4B), the estimated MCID for AIMS total score was
3 points. The mean change from baseline in AIMS total
score was –3.4 (0.4), corresponding to a percent improve-
ment of 31.0% (5.3%). The median score change was –3
(range, –13 to 8).
TABLE 1. Baseline characteristics (pooled ITT population)
Placebo (n = 158)
Valbenazine Low
Dose* (n = 114)
Valbenazine High
Dose** (n = 101)
Age, mean (SD), years 55.8 (10.1) 54.9 (9.1) 56.2 (10.4)
Male, n (%) 89 (56.3) 72 (63.2) 55 (54.5)
Race, n (%)
White 86 (54.4) 64 (56.1) 62 (61.4)
Black or African American 63 (39.9) 44 (38.6) 36 (35.6)
Psychiatric diagnosis group, n (%)
Schizophrenia/schizoaffective disorder 116 (73.4) 90 (78.9) 61 (60.4)
Mood disorder 42 (26.6) 24 (21.1) 40 (39.6)
Concomitant use of antipsychotics, n (%)
Any antipsychotic 130 (82.3) 102 (89.5) 77 (76.2)
Atypical only 102 (78.5) 77 (75.5) 63 (81.8)
Typical only or both 28 (21.5) 25 (24.5) 14 (18.2)
BPRS score at screening, mean (SD) 30.5 (7.6) 31.6 (7.9) 28.9 (6.8)
AIMS total score at baseline
Mean (SD) 8.9 (4.4) 9.0 (4.2) 9.5 (3.6)
Median (minimum, maximum) 8 (1, 26) 9 (0, 20) 9 (3, 20)
*Includes participants who received valbenazine 40 or 50 mg/day.
**Includes participants who received valbenazine 75 or 80 mg/day.
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Similar to results for CGI-TD score ≤3, analyses based
on PGIC score ≤3 yielded an MCID estimation of 2 points,
with amedian 20% improvement from baseline (Supporting
Information Appendix; Supporting Information Table S1).
Analyses based on PGIC score ≤2 also yielded anMCID esti-
mation of 2 points (compared to 3 points for CGI-TD
score ≤3), with amedian 30% total score improvement from
baseline.
Discussion
Although the AIMS total score is the current standard
for determining efﬁcacy in TD clinical trials, translating
this outcome into clinical practice can be challenging.16
To address that challenge, the TD Workshop participants
discussed different ways to analyze AIMS data and identi-
ﬁed the MCID as one possible approach.17 Based on both
clinician- and patient-rated anchors of minimal improve-
ment (CGI-TD and PGIC score ≤3 at week 6), mean and
median changes in AIMS total score (sum of items 1-7)
suggested anMCID of 2 points in adults with TD. Analyses
based on more rigorous deﬁnitions of global improvement
(CGI-TD and PGIC score ≤2 at week 6) suggested a
clinician-based MCID of 3 points and a patient-based
MCID of 2 to 3 points. Clinically, these proposed MCIDs
may be useful for interpreting the effects of treatment on
TD. However, it may be worth noting that the MCID of
2 points is consistent with the distribution-based approach
that uses 0.5 times the baseline SD as a threshold for clini-
cally meaningful change.18 In the pooled data set, the SD of
the mean AIMS total score at baseline in all participants
was 4.2, whichwould correspond to anMCID of 2 points.
The current results were consistent with preliminary
MCID analyses, which only included CGI-TD anchors.19,20
PGIC anchors were added to the current analyses to address
the need for more patient-reported outcomes in TD studies.
Given that patients with TD can be unaware of their
movements,21 these PGIC-based results should be inter-
preted with some caution. However, consistent with the
CGI-TD results, MCID estimates based on patient-reported
improvements suggest that a 2- to 3-point decrease in AIMS
total score may be considered clinically meaningful. It
should also be noted that both anchor-basedmethods (CGI-
TD and PGIC) included placebo responders to lessen the
risk of the MCID being speciﬁc to valbenazine treatment.
Additional MCID analyses based on data from other TD
clinical trials (e.g., deutetrabenazine) would help to further
FIG. 2. AIMS total score mean change from baseline to week
6. ***P < 0.001 versus placebo.
FIG. 3. CGI-TD response at week 6. *P < 0.05; **P < 0.01; ***P < 0.001 versus placebo. CI, conﬁdence interval.
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establish whether an AIMSMCID of 2 to 3 points is appli-
cable to different TD therapies.
An additional goal of the current analysis was to include
percentage-basedMCIDs for the AIMS total score. Partici-
pants with a CGI-TD or PGIC score ≤3 at week 6 had
approximately 20% improvement from baseline in AIMS
total score. Participants with a CGI-TD or PGIC score ≤2
had approximately 30% to 40% improvement from base-
line in AIMS total score. These percentages are consistent
with earlier TD studies that deﬁned response as a ≥30%
improvement in AIMS total score.16 They are also consis-
tent with results from the companion piece to this article,
which presents a full range of AIMS total score responses
(≥10% to ≥90% improvement from baseline to week 6).17
In that analysis, the percentage of participants who
achieved a ≥20%, ≥30%, or ≥40% AIMS total score
response was signiﬁcantly higher with valbenazine high
dose versus placebo. These results were clinically meaning-
ful, as indicated by ORs for response (OR ≥4 for
valbenazine vs. placebo) and NNTs (of 3 or 4). In the
valbenazine clinical trials, AIMS response was deﬁned a
priori as ≥50% total score improvement,9,10 which ismore
stringent than the 20% to 40%MCID-based results in the
current analysis. Therefore, a greater percentage of
patients experienced a clinical beneﬁt in the valbenazine
clinical trials than the published ≥50% response analyses
would imply.
A number of limitations should be noted. First, all ana-
lyses were conducted post hoc. None of the valbenazine tri-
als were designed for estimation of an MCID, and the
pooled valbenazine dose groups included participants who
received slightly different low doses (40 and 50 mg/day)
and high doses (75 and 80 mg/day). Second, results of the
analyses may not be generalizable to all patients with
TD. The trials primarily included psychiatric patients who
were exposed to antipsychotic medications, and MCIDs
may be different in nonpsychiatric patients who were
exposed to an antiemetic (e.g., metoclopramide) or other
DRBA. Study participants were also required to be psychi-
atrically stable, whichmay not always be true in real-life set-
tings. In addition, participants in the valbenazine studies
were required to have moderate or severe TD based on the
FIG. 4. Estimation of AIMS MCID. Based on all participants who met CGI-TD response criteria regardless of treatment (valbenazine or placebo).
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qualitative assessment of an external reviewer at screening.
However, some hadminimal or mild TD at baseline (AIMS
total score range: 0–20), probably attributed to the natural
variability of dyskinetic movements.22,23 The MCID ana-
lyses were conducted without considering the AIMS total
score at baseline. Nor did they consider AIMS items scores
at baseline, which provide more speciﬁc information about
the location and severity of dyskinetic movements. To
address some of these issues, shift analyses based on AIMS
item scores were included in the companion piece to this
article.17
Limitations of the AIMS itself should also be consid-
ered. Given that the AIMS total score is the current
“gold standard” for evaluating efﬁcacy in TD clinical
trials, determining an MCID based on this measure is a
reasonable endeavor. However, the AIMS does not cap-
ture the social and functional deﬁcits associated with
TD. In addition, one-time or episodic complications
related to TD, such as a fall related to gait problems,
are not adequately captured by the AIMS. Improve-
ments in these domains must be considered along with
dyskinetic movements when determining whether a
patient is experiencing clinically meaningful improve-
ments. Methodologies for administering and scoring the
AIMS should also be considered. The proposed MCIDs
presented in this report are based on AIMS evaluations
that were scored by consensus between two central video
raters (movement disorder specialists) who were blinded
to treatment and study visit. In clinical settings, the AIMS
is administered and assessed in real time by a physician or
other qualiﬁed professional who knows what the patient
is taking and how long he or she has been treated. There-
fore, an MCID based on clinical trial data, as investigated
in this report, should be considered as more of a guideline
(rather than an imperative) for everyday practice. Given
that the analyses in this report are limited to valbenazine
data, they may not be generalizable to all AIMS results,
including those that have been reported in other TD clini-
cal trials (e.g., deutetrabenazine). Applying the proposed
MCIDs from this report to other TD trials should also be
done with caution given that differences in study design
(e.g., double-blind vs. open-label, treatment duration, eli-
gibility criteria, and allowance of concomitant medica-
tions) may affect treatment outcomes.
Finally, as previously published,15 the limitations of
anchor-based methods should be mentioned. First, differ-
ent anchors may result in different MCIDs, although the
current analysis showed consistency between clinician-
based (CGI-TD) and patient-based (PGIC) anchors.
Moreover, MCIDs from both anchor types were consis-
tent with a commonly used distribution method (i.e., 0.5
times the SD). In addition, anchors can be susceptible to
recall bias, and inter-rater agreement was not tested for
clinicians or study participants.
Despite these various limitations, the TD Workshop
participants agreed that the AIMS MCID can be an
important advancement for clinicians who treat patients
with TD. Taken in conjunction with other types of ana-
lyses (e.g., placebo-corrected mean change, effect size,
treatment response, and NNT), or even added prospec-
tively to statistical analysis plans, the MCID might help
translate trial data into clinically meaningful information.
Based on both clinician- and patient-rated anchors, the
results of this analysis suggest that a 2-point decrease in
AIMS total score may be considered an MCID if minimal
improvement is the treatment goal; a 3-point decrease
may be the MCID if more robust improvement is desired.
Much more research is needed to understand the impact
of TD on patients and caregivers, including the bench-
marks of physical, functional, and social improvements
that constitute a truly meaningful clinical difference.
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